These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8436216)

  • 21. Detection of interleukin-6 (IL-6) in human bone marrow myeloma cells by light and electron microscopy.
    Ohtake K; Yano T; Kameda K; Ogawa T
    Am J Hematol; 1990 Oct; 35(2):84-7. PubMed ID: 2205096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal by cobalamin therapy of minimal defects in the deoxyuridine suppression test in patients without anemia: further evidence for a subtle metabolic cobalamin deficiency.
    Carmel R
    J Lab Clin Med; 1992 Mar; 119(3):240-4. PubMed ID: 1541874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of interleukin-6 levels in the bone marrow of multiple myeloma patients with disease severity and clonogenicity in vitro.
    Bell JB; Montes A; Gooding R; Riches P; Cunningham D; Millar BC
    Leukemia; 1991 Nov; 5(11):958-61. PubMed ID: 1961036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
    Yen CH; Hsiao HH
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma.
    Ludwig C; Williams DS; Bartlett DB; Essex SJ; McNee G; Allwood JW; Jewell E; Barkhuisen A; Parry H; Anandram S; Nicolson P; Gardener C; Seymour F; Basu S; Dunn WB; Moss PA; Pratt G; Tennant DA
    Blood Cancer J; 2015 Oct; 5(10):e359. PubMed ID: 26473531
    [No Abstract]   [Full Text] [Related]  

  • 26. Distortions of normal bone cell metabolism induced in multiple myeloma.
    Nichols G; Cohen P
    Metabolism; 1969 Jan; 18(1):38-49. PubMed ID: 4303660
    [No Abstract]   [Full Text] [Related]  

  • 27. Iron in neoplastic cells of plasma cell myeloma.
    Vidulich K; Hanks D; Etzell JE
    Am J Hematol; 2006 Mar; 81(3):216-7. PubMed ID: 16493624
    [No Abstract]   [Full Text] [Related]  

  • 28. The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi.
    Castellani M; Carletto M; Baldini L; Calori R; Longari V; Soligo D; Dellavedova L; Gerundini P
    Clin Nucl Med; 2010 Jan; 35(1):1-5. PubMed ID: 20026963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cobalamin absorption and serum homocysteine and methylmalonic acid in elderly subjects with low serum cobalamin.
    Joosten E; Pelemans W; Devos P; Lesaffre E; Goossens W; Criel A; Verhaeghe R
    Eur J Haematol; 1993 Jul; 51(1):25-30. PubMed ID: 8348941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peanut agglutinin shows specificity for bone marrow plasma cells.
    Rhodes EG; Flynn M
    Br J Haematol; 1989 Feb; 71(2):183-7. PubMed ID: 2466473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma.
    Durie BG; Salmon SE; Mundy GR
    Br J Haematol; 1981 Jan; 47(1):21-30. PubMed ID: 7437344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of transcobalamins I, II, and III in the transfer of vitamin B12 to human bone marrow cells in vitro.
    Wickramasinghe SN; England JM; Saunders JE; Down MC
    Acta Haematol; 1975; 54(2):89-94. PubMed ID: 808945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid evolution of multiple myeloma after cobalamin therapy for megaloblastic erythropoiesis with macrocytic anemia.
    Schleinitz N; Costello R; Veit V; Swiader L; Harle JR; Bouabdallah R; Sainty D; Gastaut JA; Weiller PJ
    Leuk Res; 1998 Mar; 22(3):287. PubMed ID: 9619920
    [No Abstract]   [Full Text] [Related]  

  • 34. Constitutive expression of IL-6-LIKE cytokines in normal bone marrow: implications for pathophysiology of myeloma.
    Barton BE; Murphy TF
    Cytokine; 2000 Oct; 12(10):1537-45. PubMed ID: 11023670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum folate and serum vitamin B12 in patients with malignant hematologie diseases.
    Hoogstraten B; Baker H; Gilbert HS
    Cancer Res; 1965 Dec; 25(11):1933-8. PubMed ID: 5216688
    [No Abstract]   [Full Text] [Related]  

  • 36. The distribution of endogenous cobalamin among cobalamin-binding proteins in the blood in normal and abnormal states.
    Carmel R
    Am J Clin Nutr; 1985 Apr; 41(4):713-9. PubMed ID: 3984925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An association between chronic neutrophilic leukaemia and multiple myeloma with a study of cobalamin-binding proteins.
    Lewis MJ; Oelbaum MH; Coleman M; Allen S
    Br J Haematol; 1986 May; 63(1):173-80. PubMed ID: 3458500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA synthesis in multiple myeloma cells following cell cycle-nonspecific chemotherapy.
    Alberts DS; Golde DW
    Cancer Res; 1974 Nov; 34(11):2911-4. PubMed ID: 4424360
    [No Abstract]   [Full Text] [Related]  

  • 39. [Cytochemical characteristics of lymphoid cells in patients with multiple myeloma].
    Lugovskaia SA
    Lab Delo; 1982; (11):643-6. PubMed ID: 6184523
    [No Abstract]   [Full Text] [Related]  

  • 40. Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma.
    Spanoudakis E; Papoutselis M; Terpos E; Dimopoulos MA; Tsatalas C; Margaritis D; Rahemtulla A; Kotsianidis I; Karadimitris A
    Blood Cancer J; 2016 Nov; 6(11):e500. PubMed ID: 27834938
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.